Vanguard Group Inc. Boosts Position in NuVasive Inc. (NUVA)

Vanguard Group Inc. increased its stake in shares of NuVasive Inc. (NASDAQ:NUVA) by 1.6% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 3,971,594 shares of the medical device company’s stock after buying an additional 62,340 shares during the period. Vanguard Group Inc. owned about 7.91% of NuVasive worth $237,184,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the stock. BNP Paribas Arbitrage SA boosted its stake in NuVasive by 11.9% in the second quarter. BNP Paribas Arbitrage SA now owns 45,084 shares of the medical device company’s stock valued at $2,692,000 after buying an additional 4,782 shares in the last quarter. State Street Corp boosted its stake in NuVasive by 1.9% in the first quarter. State Street Corp now owns 1,079,736 shares of the medical device company’s stock valued at $52,522,000 after buying an additional 20,644 shares in the last quarter. Hood River Capital Management LLC acquired a new stake in shares of NuVasive during the second quarter valued at about $25,307,000. Kennedy Capital Management Inc. raised its stake in shares of NuVasive by 2.6% in the first quarter. Kennedy Capital Management Inc. now owns 34,610 shares of the medical device company’s stock valued at $1,684,000 after buying an additional 891 shares during the last quarter. Finally, Aperio Group LLC raised its stake in shares of NuVasive by 11.1% in the first quarter. Aperio Group LLC now owns 7,541 shares of the medical device company’s stock valued at $367,000 after buying an additional 753 shares during the last quarter.

Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

Shares of NuVasive Inc. (NASDAQ:NUVA) opened at 66.29 on Friday. The company’s 50 day moving average is $66.26 and its 200 day moving average is $59.07. The company has a market cap of $3.33 billion, a P/E ratio of 68.77 and a beta of 0.51. NuVasive Inc. has a one year low of $36.81 and a one year high of $69.50.

NuVasive (NASDAQ:NUVA) last released its quarterly earnings data on Tuesday, July 26th. The medical device company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. NuVasive had a net margin of 5.28% and a return on equity of 10.57%. The firm had revenue of $236.50 million for the quarter, compared to analyst estimates of $232.86 million. During the same period last year, the firm earned $0.31 earnings per share. The business’s quarterly revenue was up 16.4% compared to the same quarter last year. On average, equities analysts predict that NuVasive Inc. will post $1.65 earnings per share for the current year.

NUVA has been the topic of several recent research reports. Jefferies Group reiterated a “buy” rating on shares of NuVasive in a research note on Wednesday, August 3rd. Brean Capital lifted their price target on shares of NuVasive from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, July 27th. Zacks Investment Research lowered shares of NuVasive from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 27th. Barclays PLC lifted their price target on shares of NuVasive from $63.00 to $71.00 and gave the company an “overweight” rating in a research note on Wednesday, July 27th. Finally, JPMorgan Chase & Co. upgraded shares of NuVasive from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $55.00 to $74.00 in a research note on Wednesday, July 13th. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $66.36.

In other NuVasive news, EVP Jason Hannon sold 11,184 shares of the firm’s stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $62.70, for a total value of $701,236.80. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Lesley H. Howe sold 3,602 shares of the firm’s stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $62.44, for a total transaction of $224,908.88. The disclosure for this sale can be found here. 4.70% of the stock is currently owned by company insiders.

About NuVasive

Nuvasive, Inc is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion.

5 Day Chart for NASDAQ:NUVA

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
McDonald’s Keeping As Much As 25% in Hong Kong and China Stores
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
President Obama Take Steps to Block Chip Maker Acquisition by Chinese Company
GoPro Planning to Cut 200 Jobs
GoPro Planning to Cut 200 Jobs
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Retailers Anticipating Strong Support for Small Business Saturday
Retailers Anticipating Strong Support for Small Business Saturday
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Eli Lilly Alzheimer’s Drug Does Not Pass the Test


 
© 2006-2016 Ticker Report. Google+.